301 related articles for article (PubMed ID: 19025451)
1. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.
Saad M; Garbuzenko OB; Minko T
Nanomedicine (Lond); 2008 Dec; 3(6):761-76. PubMed ID: 19025451
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.
Pakunlu RI; Wang Y; Tsao W; Pozharov V; Cook TJ; Minko T
Cancer Res; 2004 Sep; 64(17):6214-24. PubMed ID: 15342407
[TBL] [Abstract][Full Text] [Related]
3. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.
Taratula O; Kuzmov A; Shah M; Garbuzenko OB; Minko T
J Control Release; 2013 Nov; 171(3):349-57. PubMed ID: 23648833
[TBL] [Abstract][Full Text] [Related]
6. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.
Taratula O; Garbuzenko OB; Chen AM; Minko T
J Drug Target; 2011 Dec; 19(10):900-14. PubMed ID: 21981718
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
Chen Y; Bathula SR; Li J; Huang L
J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
Misra R; Das M; Sahoo BS; Sahoo SK
Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
[TBL] [Abstract][Full Text] [Related]
11. Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology.
Xu PY; Kankala RK; Pan YJ; Yuan H; Wang SB; Chen AZ
Int J Nanomedicine; 2018; 13():4685-4698. PubMed ID: 30154654
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin.
Pakunlu RI; Cook TJ; Minko T
Pharm Res; 2003 Mar; 20(3):351-9. PubMed ID: 12669953
[TBL] [Abstract][Full Text] [Related]
13. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice.
Mainelis G; Seshadri S; Garbuzenko OB; Han T; Wang Z; Minko T
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):345-54. PubMed ID: 23530772
[TBL] [Abstract][Full Text] [Related]
14. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
15. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
[TBL] [Abstract][Full Text] [Related]
16. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
17. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy.
Kang XJ; Wang HY; Peng HG; Chen BF; Zhang WY; Wu AH; Xu Q; Huang YZ
Acta Pharmacol Sin; 2017 Jun; 38(6):885-896. PubMed ID: 28479604
[TBL] [Abstract][Full Text] [Related]
18. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
[TBL] [Abstract][Full Text] [Related]
19. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
20. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]